Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated at StockNews.com

StockNews.com assumed coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research report sent to investors on Tuesday morning. The brokerage issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Stock Down 4.6 %

Shares of NYSE:BTX opened at $1.04 on Tuesday. The stock has a market capitalization of $61.18 million, a PE ratio of -0.48 and a beta of 4.61. The firm’s 50 day moving average price is $1.30 and its 200-day moving average price is $1.69. Brooklyn ImmunoTherapeutics has a twelve month low of $0.17 and a twelve month high of $10.10.

Brooklyn ImmunoTherapeutics Company Profile

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.